Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel Free CABA Stock Alerts

Cabaletta Bio (CABA) Competitors

Cabaletta Bio logo
$4.15 +0.32 (+8.36%)
Closing price 04:00 PM Eastern
Extended Trading
$4.13 -0.02 (-0.48%)
As of 06:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CABA vs. MAZE, MPLT, ABCL, GHRS, and CMPS

Should you be buying Cabaletta Bio stock or one of its competitors? The main competitors of Cabaletta Bio include Maze Therapeutics (MAZE), Maplight Therapeutics (MPLT), AbCellera Biologics (ABCL), GH Research (GHRS), and Compass Pathways (CMPS). These companies are all part of the "pharmaceutical products" industry.

How does Cabaletta Bio compare to Maze Therapeutics?

Maze Therapeutics (NASDAQ:MAZE) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

Maze Therapeutics has higher revenue and earnings than Cabaletta Bio. Maze Therapeutics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maze Therapeutics$167.50M7.89-$131.12M-$3.23N/A
Cabaletta BioN/AN/A-$167.86M-$2.28N/A

Maze Therapeutics' return on equity of -40.70% beat Cabaletta Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Maze TherapeuticsN/A -40.70% -36.03%
Cabaletta Bio N/A -121.73%-90.19%

Maze Therapeutics has a beta of 2.5, suggesting that its share price is 150% more volatile than the S&P 500. Comparatively, Cabaletta Bio has a beta of 3.18, suggesting that its share price is 218% more volatile than the S&P 500.

Maze Therapeutics currently has a consensus price target of $66.00, indicating a potential upside of 148.49%. Cabaletta Bio has a consensus price target of $17.00, indicating a potential upside of 309.64%. Given Cabaletta Bio's higher probable upside, analysts plainly believe Cabaletta Bio is more favorable than Maze Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Maze Therapeutics
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.00
Cabaletta Bio
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71

In the previous week, Cabaletta Bio had 3 more articles in the media than Maze Therapeutics. MarketBeat recorded 7 mentions for Cabaletta Bio and 4 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 0.78 beat Cabaletta Bio's score of 0.47 indicating that Maze Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Maze Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cabaletta Bio
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Maze Therapeutics beats Cabaletta Bio on 8 of the 13 factors compared between the two stocks.

How does Cabaletta Bio compare to Maplight Therapeutics?

Cabaletta Bio (NASDAQ:CABA) and Maplight Therapeutics (NASDAQ:MPLT) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Maplight Therapeutics' return on equity of 0.00% beat Cabaletta Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Cabaletta BioN/A -121.73% -90.19%
Maplight Therapeutics N/A N/A N/A

Cabaletta Bio is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cabaletta BioN/AN/A-$167.86M-$2.28N/A
Maplight TherapeuticsN/AN/A-$161.15M-$39.65N/A

In the previous week, Maplight Therapeutics had 7 more articles in the media than Cabaletta Bio. MarketBeat recorded 14 mentions for Maplight Therapeutics and 7 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 0.47 beat Maplight Therapeutics' score of 0.37 indicating that Cabaletta Bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cabaletta Bio
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Maplight Therapeutics
5 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Cabaletta Bio presently has a consensus price target of $17.00, suggesting a potential upside of 309.64%. Maplight Therapeutics has a consensus price target of $34.43, suggesting a potential upside of 23.31%. Given Cabaletta Bio's higher possible upside, research analysts plainly believe Cabaletta Bio is more favorable than Maplight Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cabaletta Bio
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
Maplight Therapeutics
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.80

Summary

Maplight Therapeutics beats Cabaletta Bio on 8 of the 11 factors compared between the two stocks.

How does Cabaletta Bio compare to AbCellera Biologics?

Cabaletta Bio (NASDAQ:CABA) and AbCellera Biologics (NASDAQ:ABCL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Cabaletta Bio has a net margin of 0.00% compared to AbCellera Biologics' net margin of -198.37%. AbCellera Biologics' return on equity of -15.05% beat Cabaletta Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Cabaletta BioN/A -121.73% -90.19%
AbCellera Biologics -198.37%-15.05%-10.92%

61.4% of AbCellera Biologics shares are held by institutional investors. 11.3% of Cabaletta Bio shares are held by company insiders. Comparatively, 28.9% of AbCellera Biologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

AbCellera Biologics has higher revenue and earnings than Cabaletta Bio. AbCellera Biologics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cabaletta BioN/AN/A-$167.86M-$2.28N/A
AbCellera Biologics$75.13M18.93-$146.41M-$0.49N/A

In the previous week, AbCellera Biologics had 1 more articles in the media than Cabaletta Bio. MarketBeat recorded 8 mentions for AbCellera Biologics and 7 mentions for Cabaletta Bio. AbCellera Biologics' average media sentiment score of 0.61 beat Cabaletta Bio's score of 0.47 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cabaletta Bio
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
AbCellera Biologics
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Cabaletta Bio presently has a consensus price target of $17.00, suggesting a potential upside of 309.64%. AbCellera Biologics has a consensus price target of $8.17, suggesting a potential upside of 75.25%. Given Cabaletta Bio's higher possible upside, research analysts plainly believe Cabaletta Bio is more favorable than AbCellera Biologics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cabaletta Bio
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
AbCellera Biologics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71

Cabaletta Bio has a beta of 3.18, suggesting that its share price is 218% more volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500.

Summary

AbCellera Biologics beats Cabaletta Bio on 10 of the 15 factors compared between the two stocks.

How does Cabaletta Bio compare to GH Research?

GH Research (NASDAQ:GHRS) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

GH Research presently has a consensus price target of $40.13, suggesting a potential upside of 87.68%. Cabaletta Bio has a consensus price target of $17.00, suggesting a potential upside of 309.64%. Given Cabaletta Bio's higher possible upside, analysts plainly believe Cabaletta Bio is more favorable than GH Research.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GH Research
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.73
Cabaletta Bio
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71

GH Research's return on equity of -16.30% beat Cabaletta Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
GH ResearchN/A -16.30% -15.77%
Cabaletta Bio N/A -121.73%-90.19%

GH Research has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Cabaletta Bio has a beta of 3.18, suggesting that its stock price is 218% more volatile than the S&P 500.

56.9% of GH Research shares are held by institutional investors. 11.3% of Cabaletta Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

GH Research is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GH ResearchN/AN/A-$48.26M-$0.80N/A
Cabaletta BioN/AN/A-$167.86M-$2.28N/A

In the previous week, Cabaletta Bio had 4 more articles in the media than GH Research. MarketBeat recorded 7 mentions for Cabaletta Bio and 3 mentions for GH Research. Cabaletta Bio's average media sentiment score of 0.47 beat GH Research's score of -0.27 indicating that Cabaletta Bio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GH Research
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cabaletta Bio
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

GH Research beats Cabaletta Bio on 7 of the 13 factors compared between the two stocks.

How does Cabaletta Bio compare to Compass Pathways?

Compass Pathways (NASDAQ:CMPS) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Compass Pathways is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Compass PathwaysN/AN/A-$287.86M-$3.09N/A
Cabaletta BioN/AN/A-$167.86M-$2.28N/A

In the previous week, Cabaletta Bio had 3 more articles in the media than Compass Pathways. MarketBeat recorded 7 mentions for Cabaletta Bio and 4 mentions for Compass Pathways. Compass Pathways' average media sentiment score of 0.70 beat Cabaletta Bio's score of 0.47 indicating that Compass Pathways is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Compass Pathways
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cabaletta Bio
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

46.2% of Compass Pathways shares are held by institutional investors. 2.8% of Compass Pathways shares are held by company insiders. Comparatively, 11.3% of Cabaletta Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Compass Pathways presently has a consensus price target of $20.45, suggesting a potential upside of 119.71%. Cabaletta Bio has a consensus price target of $17.00, suggesting a potential upside of 309.64%. Given Cabaletta Bio's higher probable upside, analysts clearly believe Cabaletta Bio is more favorable than Compass Pathways.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Compass Pathways
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82
Cabaletta Bio
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71

Compass Pathways has a beta of 2.39, meaning that its share price is 139% more volatile than the S&P 500. Comparatively, Cabaletta Bio has a beta of 3.18, meaning that its share price is 218% more volatile than the S&P 500.

Cabaletta Bio's return on equity of -121.73% beat Compass Pathways' return on equity.

Company Net Margins Return on Equity Return on Assets
Compass PathwaysN/A -192.95% -61.31%
Cabaletta Bio N/A -121.73%-90.19%

Summary

Cabaletta Bio beats Compass Pathways on 8 of the 14 factors compared between the two stocks.

Get Cabaletta Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CABA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CABA vs. The Competition

Export
MetricCabaletta BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$462.00M$3.39B$6.25B$11.87B
Dividend YieldN/A2.20%2.73%5.21%
P/E Ratio-1.8238.8529.0428.47
Price / SalesN/A155.51476.6160.92
Price / CashN/A57.8827.6236.52
Price / Book3.587.039.676.67
Net Income-$167.86M$23.62M$3.55B$332.53M
7 Day Performance45.10%3.68%1.70%2.01%
1 Month Performance40.20%7.16%5.62%9.19%
1 Year Performance224.22%67.05%34.41%39.59%

Cabaletta Bio Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CABA
Cabaletta Bio
2.2628 of 5 stars		$4.15
+8.4%		$17.00
+309.6%		N/A$462.00MN/AN/A50
MAZE
Maze Therapeutics
3.3356 of 5 stars		$26.47
+2.6%		$66.00
+149.3%		N/A$1.28B$167.50MN/A121
MPLT
Maplight Therapeutics
3.1645 of 5 stars		$30.64
+3.0%		$32.67
+6.6%		N/A$1.26BN/AN/A109
ABCL
AbCellera Biologics
2.7533 of 5 stars		$4.16
+0.2%		$8.40
+101.9%		N/A$1.26B$75.13MN/A500
GHRS
GH Research
2.214 of 5 stars		$19.59
-3.3%		$40.13
+104.8%		N/A$1.26BN/AN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CABA) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel